ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

Biotechnology Innovation Organization trade show is expected to bring about 20,000 participants to Boston starting on Monday.

Our process uses bottom-up financial analysis aimed at identifying large-cap companies that we think have the potential to ...

Worldwide Healthcare Trust PLC - Annual Financial Report PR Newswire LONDON, United Kingdom, June 11 10 June 2025Worldwide Healthcare Trust PLC(the "Company") Annual Financial ...

Vera Therapeutics Inc. research and ratings by Barron's. View VERA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Owing to the growing need for new drug classes, demand for oligonucleotide APIs is projected to rise at a high CAGR of 5.60% from 2024 to 2034. As such, the global oligonucleotide API market is ...